Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic TCR-enhanced Vδ2 T Cell Injection in Malignant Tumors
NCT07570563Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jun 2026
- Primary completion
- Jun 2029
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in hematologic malignancy and solid tumor, sponsored by Chinese PLA General Hospital. Primary endpoints: Adverse Event at 12 months and Dose-Limiting Toxicities at 28 days. Started Jun 2026; status: recruiting.
02
Conditions
hematologic malignancysolid tumor
Beyond the preview
Go deeper on NCT07570563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07570563.